ZURA — Zura Bio Ltd
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1855644 ·
Last close
$5.11
Market Cap
$484.84M
52W High
$6.01
52W Low
$3.25
ADV30
1,485,012
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -25,499,000 | -24,223,000 | 228,641,000 | 225,594,000 | 11,745,000 |
| Dec 2025 | 0 | — | -18,411,000 | -17,175,000 | 113,948,000 | 109,407,000 | 12,410,000 |
| Sep 2025 | 0 | — | -19,519,000 | -18,040,000 | 143,935,000 | 139,017,000 | 25,491,000 |
| Jun 2025 | 0 | — | -18,062,000 | -15,993,000 | 157,805,000 | 154,490,000 | 18,696,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,815,000
Investing CF
$-113,000
Financing CF
$-2,163,000
CapEx
$-113,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.83
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-224,547,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-75,246,000
Pretax Income TTM
$-68,650,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -75,246,000 | -68,650,000 | 113,948,000 | 12,410,000 | — | -64,815,000 |
| Dec 2024 | 0 | -55,189,000 | -52,403,000 | 179,533,000 | 19,514,000 | — | -28,076,000 |
| Dec 2023 | 0 | -62,638,000 | -60,360,000 | 100,843,000 | 21,292,000 | — | -15,054,000 |
| Dec 2022 | 0 | -27,162,000 | -25,738,000 | 5,262,000 | 27,318,000 | — | -1,202,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.50
Max Pain — expiry 2026-07-17
max pain strike: $5.00 · spot: $5.11 · call oi: 939 · put oi: 64
Expected Move to 2026-07-17:
±$0.50
(9.78%) —
implied range
$4.61 –
$5.61
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNA | Ginkgo Bioworks Holdings, Inc. | $485.05M | $9.09 | — |
| CABA | Cabaletta Bio, Inc. | $485.09M | $2.97 | — |
| STRO | SUTRO BIOPHARMA, INC. | $492.64M | $29.73 | — |
| OCGN | Ocugen, Inc. | $497.63M | $1.47 | — |
| EDIT | Editas Medicine, Inc. | $500.29M | $3.26 | — |
News headlines (Yahoo Finance, 1h cache)
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
2026-06-29 11:30 · Yahoo
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
2026-06-03 10:09 · Yahoo
One Zura Bio Insider Raised Their Stake In The Previous Year
2026-04-23 10:06 · Yahoo
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
2026-02-25 20:26 · Yahoo
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges
2026-02-25 20:19 · Yahoo
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst
2026-02-25 20:11 · Yahoo
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
2026-02-16 11:03 · Yahoo
December 2025's Top Penny Stocks With Promising Potential
2025-12-15 18:05 · Yahoo
Bullish Outlook on Zura Bio Limited (ZURA) Amid Tibulizumab Phase 2 Clinical Trial Progress
2025-11-29 06:26 · Yahoo
Zura Bio And 2 Other Promising Penny Stocks For Your Watchlist
2025-10-28 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.